MIC Versus MBEC to Determine the Antibiotic Sensitivity of Staphylococcus aureus in Peritoneal Dialysis Peritonitis

被引:50
作者
Girard, Louis P. [1 ]
Ceri, Howard [2 ]
Gibb, Allan P.
Olson, Merle [2 ]
Sepandj, Farshad [1 ]
机构
[1] Univ Calgary, Dept Med, Div Nephrol, Calgary, AB, Canada
[2] Univ Calgary, Dept Biol Sci Microbiol & Infect Dis, Biofilm Res Grp, Calgary, AB, Canada
来源
PERITONEAL DIALYSIS INTERNATIONAL | 2010年 / 30卷 / 06期
关键词
Biofilms; antibiotics; peritonitis; RESIDUAL RENAL-FUNCTION; BACTERIAL BIOFILMS; INFECTIONS; CEFAZOLIN;
D O I
10.3747/pdi.2010.00010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Peritoneal dialysis (PD)-related peritonitis is a common and morbid complication of PD. Bacteria are able to create a biofilm on the PD catheter, which can be a source of recurrent infection. Biofilms undergo a phenotypic change resulting in increased antibiotic resistance. Methods: 21 clinical isolates of different patients with PD peritonitis secondary to Staphylococcus aureus were collected. They were analyzed for their antibiotic susceptibility in the planktonic form using the standard minimum inhibitory concentration (MIC) and in a biofilm using minimum biofilm eradication concentration (MBEC). Chi-square was used to compare the sensitivity results. Results: The isolates were susceptible to all the antibiotics tested using MIC. Every antibiotic except gentamicin lost its efficacy when the bacteria were grown in a biofilm (p > 0.05). The change in susceptibility was statistically significant to a level of p < 0.001 for all antibiotics tested. Discussion: In PD peritonitis that is long standing, recurrent, or not responsive to therapy, MBEC testing should be considered as a biofilm may be present. Gentamicin should be strongly considered over other agents for empiric gram-negative coverage as it may be providing synergy in the setting of Staphylococcus aureus. Also, the newer antistaphylococcal drugs should be tested for their performance in a biofilm using the MBEC method.
引用
收藏
页码:652 / 656
页数:5
相关论文
共 15 条
[1]   Empirical aminoglycosides for peritonitis do not affect residual renal function [J].
Baker, RJ ;
Senior, H ;
Clemenger, M ;
Brown, EA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :670-675
[2]   The MBEC assay system: Multiple equivalent biofilms for antibiotic and biocide susceptibility testing [J].
Ceri, H ;
Olson, M ;
Morck, D ;
Storey, D ;
Read, R ;
Buret, A ;
Olson, B .
MICROBIAL GROWTH IN BIOFILMS, PT B: SPECIAL ENVIRONMENTS AND PHYSICOCHEMICAL ASPECTS, 2001, 337 :377-385
[3]   The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms [J].
Ceri, H ;
Olson, ME ;
Stremick, C ;
Read, RR ;
Morck, D ;
Buret, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1771-1776
[4]  
Clinical and Laboratory Standards Institute, 2009, METH DIL ANT SUSC TE
[5]   BACTERIAL BIOFILMS IN NATURE AND DISEASE [J].
COSTERTON, JW ;
CHENG, KJ ;
GEESEY, GG ;
LADD, TI ;
NICKEL, JC ;
DASGUPTA, M ;
MARRIE, TJ .
ANNUAL REVIEW OF MICROBIOLOGY, 1987, 41 :435-464
[6]   DEVELOPMENT OF BACTERIAL BIOFILMS ON SILASTIC CATHETER MATERIALS IN PERITONEAL-DIALYSIS FLUID [J].
DASGUPTA, MK ;
WARD, K ;
NOBLE, PA ;
LARABIE, M ;
COSTERTON, JW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (05) :709-716
[7]   SIGNIFICANCE OF BIOFILM-ADHERENT BACTERIAL MICROCOLONIES ON TENCKHOFF CATHETERS OF CAPD PATIENTS [J].
DASGUPTA, MK ;
COSTERTON, JW .
BLOOD PURIFICATION, 1989, 7 (2-3) :144-155
[8]  
Demoulin N, 2009, PERITON DIALYSIS INT, V29, P548
[9]   Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model [J].
Hermsen, ED ;
Hovde, LB ;
Hotchkiss, JR ;
Rotschafer, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3764-3767
[10]   Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: Effect on residual renal function [J].
Lui, SL ;
Cheng, SW ;
Ng, F ;
Ng, SY ;
Wan, KM ;
Yip, T ;
Tse, KC ;
Lam, MF ;
Lai, KN ;
Lo, WK .
KIDNEY INTERNATIONAL, 2005, 68 (05) :2375-2380